Skip to main content

Margetuximab Side Effects

Medically reviewed by Last updated on Oct 14, 2023.

Applies to margetuximab: intravenous solution.


Intravenous route (Solution)

Warning: Left Ventricular Dysfunction and Embryo-fetal ToxicityLeft Ventricular Dysfunction: Margetuximab-cmkb may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue margetuximab-cmkb treatment for a confirmed clinically significant decrease in left ventricular function.Embryo-fetal Toxicity: Exposure to margetuximab-cmkb during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.

Serious side effects of Margetuximab

Along with its needed effects, margetuximab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking margetuximab:

More common

Other side effects of Margetuximab

Some side effects of margetuximab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to margetuximab: intravenous solution.


Very common (10% or more): Decreased hemoglobin (52%;), decreased leukocytes (40%), decreased lymphocytopenia (31%), increased INR (24%;), increased aPTT (32%)

Common (1% to 10%): Febrile neutropenia (1.5%), neutropenia/neutrophil count decrease (1.5%)[Ref]


Common (1% to 10%): Immunogenicity (1.7%)[Ref]


Very common (10% or more): Myalgia (14%), arthralgia (14%), extremity pain (11%)[Ref]


Very common (10% or more): Increased serum alanine aminotransferase (32%), increased serum aspartate aminotransferase (23%), increased serum alkaline phosphatase (21%)[Ref]


Very common (10% or more): Cough (14%), dyspnea (13%)

Uncommon (0.1% to 1%): Aspiration pneumonia (0.4%), viral pneumonia(0.8%)[Ref]


Very common (10% or more): Fatigue/Asthenia (57%), pyrexia (19%), infusion related reaction (13%)

Common (1% to 10%): Fatal adverse reactions (1.1%)[Ref]

Nervous system

Very common (10% or more): Headache (19%), peripheral neuropathy (16%)

Common (1% to 10%): Dizziness (10%), insomnia (6%)[Ref]


Very common (10% or more): Increased serum creatinine (68%)[Ref]


Common (1% to 10%): Hypertension (5%), left ventricular dysfunction (1.9%), syncope (1.5%)[Ref]


Very common (10% or more): Alopecia (18%), palmar-plantar erythrodysesthesia (13%)

Common (1% to 10%): Skin rash (6%)[Ref]


Common (1% to 10%): Decreased weight (6%), increased serum lipase (30%),[Ref]


Very common (10% or more): Abdominal pain (17%), constipation (19%), increased serum lipase (30%), decreased appetite (14%), nausea (33%), vomiting (21%), diarrhea (25%)

Common (1% to 10%): Dysgeusia (6%), stomatitis (10%)[Ref]


1. (2021) "Product Information. Margenza (margetuximab)." Almirall

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.